Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch

Amylyx Pharmaceuticals (NASDAQ: AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with Phase 3 data expected in the third quarter and preparations underway for a potential commercial launch in 2027, Chief Financial Officer Jim Frates said during a Needham investor session hosted by biotech analyst Ami Fadia. Frates said